527 related articles for article (PubMed ID: 30366512)
1. Identifying the novel inhibitors of lysine-specific demethylase 1 (LSD1) combining pharmacophore-based and structure-based virtual screening.
Sun XD; Zheng YC; Ma CY; Yang J; Gao QB; Yan Y; Wang ZZ; Li W; Zhao W; Liu HM; Ding L
J Biomol Struct Dyn; 2019 Oct; 37(16):4200-4214. PubMed ID: 30366512
[TBL] [Abstract][Full Text] [Related]
2. Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration.
Zheng YC; Duan YC; Ma JL; Xu RM; Zi X; Lv WL; Wang MM; Ye XW; Zhu S; Mobley D; Zhu YY; Wang JW; Li JF; Wang ZR; Zhao W; Liu HM
J Med Chem; 2013 Nov; 56(21):8543-60. PubMed ID: 24131029
[TBL] [Abstract][Full Text] [Related]
3. Raloxifene, identified as a novel LSD1 inhibitor, suppresses the migration of renal cell carcinoma.
Ma Y; Zheng Y; Ji Y; Wang X; Ye B
Future Med Chem; 2021 Mar; 13(6):533-542. PubMed ID: 33527838
[No Abstract] [Full Text] [Related]
4. Identification of Novel Selective Lysine-Specific Demethylase 1 (LSD1) Inhibitors Using a Pharmacophore-Based Virtual Screening Combined with Docking.
Zhou C; Kang D; Xu Y; Zhang L; Zha X
Chem Biol Drug Des; 2015 Jun; 85(6):659-71. PubMed ID: 25346381
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
Duan YC; Jin LF; Ren HM; Zhang SJ; Liu YJ; Xu YT; He ZH; Song Y; Yuan H; Chen SH; Guan YY
Eur J Med Chem; 2021 Aug; 220():113453. PubMed ID: 33957387
[TBL] [Abstract][Full Text] [Related]
6. [1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.
Li ZH; Ma JL; Liu GZ; Zhang XH; Qin TT; Ren WH; Zhao TQ; Chen XH; Zhang ZQ
Eur J Med Chem; 2020 Feb; 187():111989. PubMed ID: 31881456
[TBL] [Abstract][Full Text] [Related]
7. Exploration of 5-cyano-6-phenylpyrimidin derivatives containing an 1,2,3-triazole moiety as potent FAD-based LSD1 inhibitors.
Ma L; Wang H; You Y; Ma C; Liu Y; Yang F; Zheng Y; Liu H
Acta Pharm Sin B; 2020 Sep; 10(9):1658-1668. PubMed ID: 33088686
[TBL] [Abstract][Full Text] [Related]
8. Discovery of tranylcypromine analogs with an acylhydrazone substituent as LSD1 inactivators: Design, synthesis and their biological evaluation.
Sun K; Peng JD; Suo FZ; Zhang T; Fu YD; Zheng YC; Liu HM
Bioorg Med Chem Lett; 2017 Nov; 27(22):5036-5039. PubMed ID: 29037950
[TBL] [Abstract][Full Text] [Related]
9. Utilizing a structure-based virtual screening approach to discover potential LSD1 inhibitors.
Fan Z; Liu X; Wang N; Yu S; Bi C; Si Y; Ling X; Liu C; Wang J; Sun H
J Cancer Res Clin Oncol; 2024 May; 150(5):253. PubMed ID: 38748285
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors.
Wang X; Zhang C; Zhang X; Yan J; Wang J; Jiang Q; Zhao L; Zhao D; Cheng M
Eur J Med Chem; 2020 May; 194():112243. PubMed ID: 32229389
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.
Duan Y; Qin W; Suo F; Zhai X; Guan Y; Wang X; Zheng Y; Liu H
Bioorg Med Chem; 2018 Dec; 26(23-24):6000-6014. PubMed ID: 30448189
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors.
Zhang X; Huang H; Zhang Z; Yan J; Wu T; Yin W; Sun Y; Wang X; Gu Y; Zhao D; Cheng M
Eur J Med Chem; 2021 Aug; 220():113501. PubMed ID: 33945992
[TBL] [Abstract][Full Text] [Related]
13. LSD1-Based Reversible Inhibitors Virtual Screening and Binding Mechanism Computational Study.
Yin Z; Liu S; Yang X; Chen M; Du J; Liu H; Yang L
Molecules; 2023 Jul; 28(14):. PubMed ID: 37513188
[TBL] [Abstract][Full Text] [Related]
14. Insight into the binding mode of a novel LSD1 inhibitor by molecular docking and molecular dynamics simulations.
Zhang X; Li M; Wang Y; Zhao Y
J Recept Signal Transduct Res; 2015; 35(5):363-9. PubMed ID: 26364657
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological activity of 4-(4-benzyloxy)phenoxypiperidines as selective and reversible LSD1 inhibitors.
Xi J; Xu S; Zhang L; Bi X; Ren Y; Liu YC; Gu Y; Xu Y; Lan F; Zha X
Bioorg Chem; 2018 Aug; 78():7-16. PubMed ID: 29524666
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of 5-aminotetrahydroquinoline-based LSD1 inhibitors acting on Asp375.
Yan J; Gu Y; Sun Y; Zhang Z; Zhang X; Wang X; Wu T; Zhao D; Cheng M
Arch Pharm (Weinheim); 2021 Aug; 354(8):e2100102. PubMed ID: 33987875
[TBL] [Abstract][Full Text] [Related]
17. A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors.
Zheng YC; Ma J; Wang Z; Li J; Jiang B; Zhou W; Shi X; Wang X; Zhao W; Liu HM
Med Res Rev; 2015 Sep; 35(5):1032-71. PubMed ID: 25990136
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of [1,2,4]triazolo[1,5-a]pyrimidines as potent lysine specific demethylase 1 (LSD1/KDM1A) inhibitors.
Wang S; Zhao LJ; Zheng YC; Shen DD; Miao EF; Qiao XP; Zhao LJ; Liu Y; Huang R; Yu B; Liu HM
Eur J Med Chem; 2017 Jan; 125():940-951. PubMed ID: 27769034
[TBL] [Abstract][Full Text] [Related]
19. Lysine-specific histone demethylase 1 (LSD1): A potential molecular target for tumor therapy.
Chen Y; Jie W; Yan W; Zhou K; Xiao Y
Crit Rev Eukaryot Gene Expr; 2012; 22(1):53-9. PubMed ID: 22339659
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures.
Ota Y; Kakizawa T; Itoh Y; Suzuki T
Molecules; 2018 May; 23(5):. PubMed ID: 29734782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
